Showing results (61-70 of 77) with videos related to

Sort By:
Pageof 8
The New England Journal of Medicine|February 15, 2023
Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older AdultsAlberto Papi, Michael G Ison, Joanne M Langley, et al.
International Journal for Quality in Health Care : Journal of the International Society for Quality in Health Care|November 18, 2021
Feedback of ATP measurement as a tool for reducing environmental contamination in hospitals in the Dutch/Belgian border areaAndreas Van Arkel, Ina Willemsen, Linda Kilsdonk-Bode, et al.
Human Vaccines & Immunotherapeutics|February 17, 2026
Safety and immunogenicity of an investigational mRNA-lipid nanoparticle-based monovalent influenza vaccine: Results from a phase 1, randomized, dose-escalation studyIsabel Leroux-Roels, Ilse De Coster, Alberto M Borobia, et al.
The Lancet. Infectious Diseases|May 14, 2021
Immunogenicity and safety of a tri-antigenic versus a mono-antigenic hepatitis B vaccine in adults (PROTECT): a randomised, double-blind, phase 3 trialTimo Vesikari, Joanne M Langley, Nathan Segall, et al.
The Journal of Infectious Diseases|July 29, 2022
Safety and Immunogenicity of a Respiratory Syncytial Virus Prefusion F (RSVPreF3) Candidate Vaccine in Older Adults: Phase 1/2 Randomized Clinical TrialIsabel Leroux-Roels, Matthew G Davis, Katie Steenackers, et al.
Lancet (London, England)|December 14, 2020
Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in healthy adults: two clinical trialsIlse De Coster, Isabel Leroux-Roels, Ananda S Bandyopadhyay, et al.
Vaccine|October 12, 2021
A new fully liquid presentation of MenACWY-CRM conjugate vaccine: Results from a multicentre, randomised, controlled, observer-blind studyCorinne Vandermeulen, Isabel Leroux-Roels, James Vandeleur, et al.
The Lancet. Respiratory Medicine|April 17, 2025
Efficacy, safety, and immunogenicity of the AS01E-adjuvanted respiratory syncytial virus prefusion F protein vaccine (RSVPreF3 OA) in older adults over three respiratory syncytial virus seasons (AReSVi-006): a multicentre, randomised, observer-blinded, placebo-controlled, phase 3 trialMichael G Ison, Alberto Papi, Eugene Athan, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 22, 2024
Efficacy and Safety of Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine (RSVPreF3 OA) in Older Adults Over 2 RSV SeasonsMichael G Ison, Alberto Papi, Eugene Athan, et al.
Open Forum Infectious Diseases|April 17, 2023
Respiratory Syncytial Virus Disease Burden in Community-Dwelling and Long-Term Care Facility Older Adults in Europe and the United States: A Prospective StudySílvia Narejos Pérez, Josep María Ramón Torrell, Airi Põder, et al.
Pageof 8